Franklin Biotechnology Discovery Fund

Portfolio Statistics

Assets

Total Fund AssetsAs of 05/31/2020 (updated monthly) $1,306.2 (M)
Net Assets - Class C As of 04/30/2020 (updated monthly) $48.3 (M)

Positions As of 05/31/2020

Equity VS. NASDAQ Biotechnology Index

Fund Benchmark
Market CapitalizationAs of 04/30/2020 (updated monthly) $33,568.32(M) $41,664.64(M)
P/B RatioAs of 04/30/2020 (updated monthly) 6.00 5.11
P/E Ratio (12-mo Forward)As of 04/30/2020 (updated monthly) 17.12 16.51
Price to Cash FlowAs of 04/30/2020 (updated monthly) 17.89 15.11

Portfolio Details

Asset AllocationAs of 05/31/2020

[name] [value]
Equity 93.63%
Cash & Cash Equivalents 6.37%

Geographic BreakdownAs of 05/31/2020

[name] [value]
United States 79.82%
Cash & Cash Equivalents 6.37%
United Kingdom 4.18%
Netherlands 3.77%
Denmark 2.36%
Canada 2.06%
Switzerland 0.82%
Germany 0.62%

sector breakdownAs of 04/30/2020

[name] [value]
Biotechnology 76.12%
Pharmaceuticals 10.61%
Cash & Cash Equivalents 8.49%
Life Sciences Tools & Services 4.77%

TOP TEN HOLDINGSAs of 05/31/2020

Issuer Country Industry % of total
VERTEX PHARMACEUTICALS INC United States Pharmaceuticals, Biotechnology & Life Sciences 7.49%
REGENERON PHARMACEUTICALS INC United States Pharmaceuticals, Biotechnology & Life Sciences 6.96%
AMGEN INC United States Pharmaceuticals, Biotechnology & Life Sciences 5.60%
ILLUMINA INC United States Pharmaceuticals, Biotechnology & Life Sciences 4.89%
GILEAD SCIENCES INC United States Pharmaceuticals, Biotechnology & Life Sciences 4.79%
BIOGEN INC United States Pharmaceuticals, Biotechnology & Life Sciences 4.45%
GW PHARMACEUTICALS PLC United Kingdom Pharmaceuticals, Biotechnology & Life Sciences 3.96%
IOVANCE BIOTHERAPEUTICS INC United States Pharmaceuticals, Biotechnology & Life Sciences 3.49%
PTC THERAPEUTICS INC United States Pharmaceuticals, Biotechnology & Life Sciences 2.92%
ARGENX SE Netherlands Pharmaceuticals, Biotechnology & Life Sciences 2.83%

Market Capitalization BreakdownAs of 05/31/2020

[name] [value]
N/A 100.00%